Just two visits a year: Longer ARV scripts, shorter clinic lines
6MMD (six multi-month dispensing) allows stable HIV patients to collect medication only twice a year, cutting down clinic visits.
Western Cape clinics began 6MMD last year, easing pressure on staff and improving retention in care through ARV clubs for stable patients.
From August, clinics countrywide will issue patients who are doing well on their ARVs, a six-month supply, twice a year. 6MMD is widespread in Africa and started in the Western Cape last year. How will it work? Health Beat catches up with two Cape clinics.
newsletter.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Almost half of NHS England waiting list patients yet to have initial appointment
Around three million people in England have had no further health care since being referred to a hospital waiting list, new data suggests. NHS England figures last month estimated 7.36 million treatments were waiting to be carried out at the end of May, relating to just under 6.23 million patients – with the analysis from MBI Health suggesting almost half of those have been left in limbo. Referring to the issue as a 'frontlog' that contributes to increasing NHS waiting list times, MBI said the problem 'has gone unchallenged for too long', with an estimated 2.99 million people waiting for their first clinical contact. MBI's analysis found that around 70% of referral to treatment pathways fall into the category of being 'unseen' since the patient's GP referred them to a specialist. Delays in making a first assessment can lead to late diagnosis, worsening symptoms and pressure on emergency services. The analysis found that ear, nose and throat (ENT), trauma and orthopaedics, gastroenterology, ophthalmology and gynaecology and obstetrics departments were consistently the specialist departments with the greatest number of patients not seen for the first time. As part of the Government's 10-year health plan, the NHS is expected to meet its target of carrying out 92% per cent of routine operations and appointments within 18 weeks by March 2029 – a target that has not been achieved for almost a decade. The latest figures show how challenging that target will be given an estimated one million of the three million unseen patients have already gone more than 18 weeks without receiving any care. 'If accurate, three million people are trapped in an invisible waiting list crisis, stuck without basic diagnostic tests of first appointments while their conditions worsen,' Rachel Power, the chief executive of the Patients Association, told the Guardian. 'The scale is staggering, as nearly half of all patients on a waiting list haven't been seen by anyone. That's not a healthcare service; that's a breakdown. 'These aren't just statistics. They're people checking their phones daily for hospital calls that never come, unable to plan their lives while their symptoms deteriorate.' Last month it was found people of working age are making up a growing proportion of those on the NHS waiting list for treatment in England. Data tables published for the first time by NHS England also show people in the most deprived parts of the country are more likely to wait more than a year to start hospital treatment than those in the least deprived. The figures, analysed by the PA news agency, showed 56.1% of those on the list at the end of June this year were of working age (defined as age 19 to 64), up from 55.8% a year ago and 55.0% in June 2022. At the same time, the proportion of people on the waiting list under the age of 19 has fallen, standing at 10.8% in June this year, down from 11.2% a year earlier and 11.9% in June 2022. The proportion who are over 65 has remained broadly unchanged at around 33.1%. People of working age are also more likely to have to wait more than a year to start treatment (3.0% of patients in this age group at the end of June) than those over 65 (2.5%). However, the proportion is the same as those under 19 (also 3.0%).
CBS News
an hour ago
- CBS News
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say
Pfizer CEO Albert Bourla is among those expected at a fundraiser President Trump is attending Friday at his golf club in Bedminster, New Jersey, sources told CBS News. The fundraiser for the pro-Trump super political action committee MAGA Inc. aims to raise about $25 million, one of the sources said. One day prior to the event, Mr. Trump sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug prices to more evenly match what other countries pay. The White House's letters to 17 drug companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and Sanofi, asked for commitments within 60 days to sell drugs for Medicaid patients and all new drugs at "most favored nation" rates. The president posted images of the letters to Truth Social. Mr. Trump signed an executive order in May telling federal officials to draw up "most favored nation" regulations unless pharmaceutical companies made progress toward cutting prices. This week's letters — which were addressed to Bourla and the other CEOs — accused the drugmakers of promising "more of the same" since then. The president said Friday he's "gone to war with the drug companies and, frankly, other countries" on the drug price issue. "I think we're going to be very successful fairly soon. We'll have drug prices coming down by 500, 600 800 even 1,200 percent," Mr. Trump said in an interview with Newsmax on Friday afternoon. The high cost of prescription drugs has vexed both parties for decades. Proposals to tie drug prices for U.S. patients to the typically much-lower rates charged in other developed countries have floated around for years, but the idea has faced some legal pushback. Meanwhile, drugmakers argue price caps could discourage innovation by making it harder to pay for research and development for new drugs. The industry also argues that Americans tend to have access to more groundbreaking drugs than residents of foreign countries with stricter price regulations — and says high drug prices are just one part of a broader trend of higher healthcare spending in the U.S. Bourla has engaged with Mr. Trump in the past. Pfizer was one of the drugmakers that was picked to rapidly develop COVID-19 vaccines in the first Trump administration's "Operation Warp Speed." And two weeks before Mr. Trump's second inauguration, Bourla and other Pfizer executives traveled to Mar-A-Lago for meetings, the Financial Times has previously reported. CBS News has reached out to Pfizer and the White House for comment.
Yahoo
2 hours ago
- Yahoo
How one small clinic proves hepatitis C doesn't have to be an epidemic
Although it's been over a decade since game-changing curative drugs for hepatitis C were approved, progress has been slow and treatment remains out of reach for many. But one small clinic in Buffalo, New York, is proving that doesn't have to be the case. Hepatitis C is a silent epidemic in the U.S., affecting up to 4 million people, according to the Centers for Disease Control and Prevention. Many people don't know they have it. Left untreated, the disease can cause cirrhosis and liver cancer. With a model that's faster, more accessible and remarkably effective, La Bodega, a clinic at Erie County Medical Center, is curing patients at a staggering rate. One of those patients is Lindsey Groffenberg, who quit drugs and was cured of Hep C at La Bodega. "When you're coming out of addiction, and you're trying to recover, the last thing you want is to feel small," she told CBS News. "When I entered La Bodega, I asked them, 'So, when's the doctor gonna come in?' And he said, 'I am the doctor.'" That doctor was Dr. Tony Martinez. "One of our mottos is 'come one, come all,'" Martinez told CBS News. "It's a very safe, stigma-free space, you know, I think people feel that when they come here." Groffenberg now helps others navigate recovery. Success stories like hers have made the clinic a model program. La Bodega gets Hep C patients on treatment in a single visit, and has a track record of curing about 98% of its 7,000-plus patients. New FDA-approved testing machines help speed up treatment. The testing machines, Martinez explained, allow them to see a patient and in that same visit confirm their diagnosis and initiate their meds. As drug costs have dropped, access should have improved, yet so far, less than a third of Americans with Hep C have been treated. Success stories like La Bodega's have policymakers seeking a national plan to eliminate Hep C. In Washington, a bipartisan bill backed by Senators Bill Cassidy and Chris Van Hollen would invest federal funds into wiping out the disease. The average patient with Hep C can rack up as much as $46,000 a year in medical costs. Treating patients early could save the government an estimated $7 billion over a decade. "This is a monumental step forward for anybody who has Hep C — they'd get access to medications," Martinez. Arkansas officials reveal new details about Devil's Den murders of husband and wife Reporter's Notebook: Diane Arbus' photography legacy Exhibition of influential photographer Diane Arbus' work opens in New York
